Real Time PCR Kit Market Scope
Real-time PCR helps in simultaneous amplification and detection of nucleic acids by the help of polymerase chain reaction (PCR). qPCR is a versatile technique which supports various research applications. Real-time PCR delivers sensitivity, specificity, and a wide dynamic range for detecting target nucleic acids. It is becoming a powerful technology for research applications which is able to cover the spectrum of biology from basic research to translational medicine to applied biology. Additionally, it is highly adopted by the pharmacological treatment, ventilators act as a vital treatment preference for COVID-19 patients. Furthermore, there is a growing requirement for a rapid production of wide range of test-kits includes antibody tests, self-administered, and others. In this COVID-19 situation the manufacturers such as Empirical bioscience revealed the enhancement of their production capacity to 50,000 kits a week to 100,000 a week. This kit helps in caters growing need for real-time COVID-19 testing. Major players revealed that they continue to accelerate their production and delivery time in the coming days.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
Key Companies Profiled | Thermo Fisher Scientific (United States), Takara Bio Inc. (Japan), F. Hoffman-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (United States), Qiagen N.V. (Germany), Agilent Technologies, Inc. (United States), Fluidigm Corporation (United States), Danaher Corporation (United States), Abbott Laboratories (United States) and Merck KGaA (Germany) |
CAGR | % |
The companies operating in this industry are focusing more on efficient growth, improvement of operational efficiency and productivity, achieving high safety standards, and focus on maintaining sustainable development. The players are focusing on securing the leading position in this industry. They are continuously looking for the opportunity to reinforce their competitive advantage. To meet a high market share, and developing socially responsible business companies are identifying various strategic pillars such as mergers & acquisitions, new product launch, product enhancement, and others. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Real Time PCR Kit market throughout the predicted period.
Thermo Fisher Scientific (United States), Takara Bio Inc. (Japan), F. Hoffman-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (United States), Qiagen N.V. (Germany), Agilent Technologies, Inc. (United States), Fluidigm Corporation (United States), Danaher Corporation (United States), Abbott Laboratories (United States) and Merck KGaA (Germany) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Becton Dickinson and Company (United States), Promega Corporation (United States) and Eppendorf AG (Germany).
About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.
Segmentation Overview
The study have segmented the market of Global Real Time PCR Kit market by Type , by Application (Gene expression (mRNA) analysis, Genetic variation analysis, MicroRNAs and noncoding RNA analysis, Virus Detection, Protein expression, Microbe detection, Fusion transcript detection, Duplexing and Others) and Region with country level break-up.
On the basis of geography, the market of Real Time PCR Kit has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
region held largest market share in the year 2023.
Market Leaders and their expansionary development strategies
In Apr 2020, Empirical Bioscience revealed their QuanTASE and QuanTASE PLUS One-Step RT-qPCR Kits under the testing protocol CDC. These kits help in identifying genetic material from the SARs-CoV-2 virus in one step. This kit converts the CoV-2 RNA to DNA and helps in detecting the presence of pathogenic material in patient samples.
In Feb 2020, QIAGEN announced the development of its shipment of QIAstat-Dx respiratory Panel COVID-19 to China. Through this initiative, the company is catering to the growing demand of automating higher-throughput processing of their laboratory-developed tests for COVID-19. Additionally, in Jan 2020, BGI revealed that they are developing a real-time fluorescent RT-PCR kit for the detection of the Novel Coronavirus. These kits are already issued to various hospitals and disease control centers.
Influencing Trend:
Technology Advancement to Detect Genetic Variations, Expansion of Compact, Portable, And Lab-On-Chip PCR Devices and Continuing Technological Integration with the PCR Process
Market Growth Drivers:
Increasing occurrence of Target Infectious Diseases and Genetic Disorders. Along with increasing Investments, Funds from governments and private players with the rising issue of COVID-19 across the globe. As it is highly adopted for the Biomarker Profiling for Disease Diagnostics. Simultaneously, an increasing the number of labs and diagnostic developers to meet the demand for detection of the SARS-CoV-2 coronavirus, across the US, European, and Asian markets.
Challenges:
Lack of Supply Chain in Underdeveloped Regions
Restraints:
High Cost Associated with the Real-Time PCR Kit and Continuous Change in The Technology
Opportunities:
Growing Market Penetration in Highest COVID-Affected Regions Such as China, The United States, Italy, And Others and Rising Shift from Plant-Derived to Genome-Based Drug Discovery
Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Real-Time PCR Kit Manufacturers, Suppliers and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries